Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Herrmann

Showing results (61-70 of 470) with videos related to

Pageof 47
Sort By:
Biological Psychiatry|July 19, 2014
Reply to: Serum zinc and the risk of depression in men: observations from a 20-year follow-up studyWalter Swardfager, Nathan Herrmann, Graham Mazereeuw, et al.
International Psychogeriatrics|September 21, 2010
Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia expertsNathan Herrmann, Sandra E Black, Abby Li, et al.
CNS Drugs|April 12, 2011
Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot studyNathan Herrmann, Jaclyn Cappell, Goran M Eryavec, et al.
Drugs|October 12, 2011
Current and emerging drug treatment options for Alzheimer's disease: a systematic reviewNathan Herrmann, Sarah A Chau, Ida Kircanski, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|May 16, 2007
Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysisSarah Thompson, Nathan Herrmann, Mark J Rapoport, et al.
Journal of Clinical Psychopharmacology|August 16, 2003
Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetineJudith Hall, Claudio A Naranjo, Beth A Sproule, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|August 31, 2006
Use of memantine to treat Alzheimer's diseaseSerge Gauthier, Nathan Herrmann, Florian Ferreri, et al.
Journal of Psychopharmacology (Oxford, England)|July 21, 2004
Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patientsNathan Herrmann, Krista L Lanctôt, Goran Eryavec, et al.
Dementia and Geriatric Cognitive Disorders|December 7, 2006
A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's diseaseNathan Herrmann, Krista L Lanctôt, Lana S Rothenburg, et al.
Drugs & Aging|June 26, 2009
Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database studyNathan Herrmann, Carin Binder, William Dalziel, et al.
Pageof 47

Showing results (61-70 of 470) with videos related to

Sort By:
Pageof 47
Biological Psychiatry|July 19, 2014
Reply to: Serum zinc and the risk of depression in men: observations from a 20-year follow-up studyWalter Swardfager, Nathan Herrmann, Graham Mazereeuw, et al.
International Psychogeriatrics|September 21, 2010
Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia expertsNathan Herrmann, Sandra E Black, Abby Li, et al.
CNS Drugs|April 12, 2011
Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot studyNathan Herrmann, Jaclyn Cappell, Goran M Eryavec, et al.
Drugs|October 12, 2011
Current and emerging drug treatment options for Alzheimer's disease: a systematic reviewNathan Herrmann, Sarah A Chau, Ida Kircanski, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|May 16, 2007
Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysisSarah Thompson, Nathan Herrmann, Mark J Rapoport, et al.
Journal of Clinical Psychopharmacology|August 16, 2003
Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetineJudith Hall, Claudio A Naranjo, Beth A Sproule, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|August 31, 2006
Use of memantine to treat Alzheimer's diseaseSerge Gauthier, Nathan Herrmann, Florian Ferreri, et al.
Journal of Psychopharmacology (Oxford, England)|July 21, 2004
Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patientsNathan Herrmann, Krista L Lanctôt, Goran Eryavec, et al.
Dementia and Geriatric Cognitive Disorders|December 7, 2006
A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's diseaseNathan Herrmann, Krista L Lanctôt, Lana S Rothenburg, et al.
Drugs & Aging|June 26, 2009
Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database studyNathan Herrmann, Carin Binder, William Dalziel, et al.
Pageof 47